SPTX Seaport Therapeutics, Inc.
$20.38▼ -4.23%
Healthcare
Other
After hours
$20.33▼ -0.26%
Oct 28, 4:46 PM ET
Volume 355.3K
Avg Volume (10D) 162.3K
Key Metrics & Fundamentals
Market Cap
$1.09B
P/E Ratio
–
Div Yield
0.00%
52W Range
14.85 - 28.38
% vs 50 MA
-4.39%
% vs 200 MA
–%
RSI-14
53.4
MACD Histogram
+0.5300
Beta (1Y vs SPY)
0.58
Free Cash Flow
-$20.17M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$27.19M
COGS
–
Operating Exp
$27.54M
Operating Income
-$27.54M
EBIT
-$27.54M
Pretax Income
-$24.89M
Net Income
-$25.41M
EPS (Diluted)
-0.48
Price & Volume History
Loading chart…
Recent News
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
Business Wire · Oct 28, 2026 7:00 AM ET
Is Seaport Therapeutics (SPTX) Overvalued Based On Book Value?
Simply Wall St. · Oct 25, 2026 6:08 PM ET
Seaport Therapeutics (SPTX) Looks Cheap After Its Cash Runway Narrative Took Center Stage
Simply Wall St. · Oct 25, 2026 11:17 AM ET
Canaccord Genuity Initiates Coverage on Seaport Therapeutics With Buy Rating, $28 Price Target
MT Newswires · Oct 14, 2026 7:20 AM ET
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Business Wire · Oct 9, 2026 1:00 PM ET
Seaport Therapeutics Says Drug Potentially Reduces Liver Impact of Depression Treatment
MT Newswires · Oct 9, 2026 8:01 AM ET
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Business Wire · Oct 9, 2026 7:00 AM ET
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Business Wire · Oct 7, 2026 1:00 PM ET
Seaport Therapeutics Doses First Patient in Phase 2a GlyphAgo Trial
MT Newswires · Oct 7, 2026 7:27 AM ET
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Business Wire · Oct 7, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SPTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.